Selective Serotonin Reuptake Inhibitor Use during Pregnancy and the Risk of Autism Spectrum Disorders: A Review

Takoua Boukhris1,2 Anick Bérard1,2

1 Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada
2 Research Center, CHU Sainte-Justine, Montreal, Quebec, Canada

J Pediatr Genet 2015;4:84–93.

Abstract
Antidepressants are widely used during pregnancy. Several studies have shown that the use of antidepressants during pregnancy is linked to adverse outcomes, including congenital malformations, prematurity, and low birth weight. However, there is a knowledge gap regarding the potential association between gestational exposure to antidepressants and the risk of autism spectrum disorders (ASD). The etiology of ASD remains unclear, although studies have implicated genetic predispositions and environmental risk factors in the development of ASD in children. In this review, we describe the association between gestational use of antidepressants, specifically selective serotonin reuptake inhibitors, and the risk of ASD.

Keywords
► SSRI
► pregnancy
► autism spectrum disorders
► review

Introduction
Antidepressants are widely used during gestation for the treatment of depression. In the United States, the prevalence of antidepressant medication use during pregnancy increased from 5.7% in 1999 to 13.3% in 20031; in Canada, 4.5% of pregnant women reported using them between 2001 and 2006.2 It remains, however, that there is continued confusion regarding their appropriate use during this critical time period. Gestational exposure to antidepressants has been associated with an increased risk of spontaneous abortion,1 major congenital malformations,3,4 prematurity,4,5 low birth weight,6,7 neonatal withdrawal,8 and pregnancy-induced hypertension.9 Discontinuation of antidepressants during pregnancy in severely depressed women was associated with relapse of maternal depression in some studies.10,11 Nevertheless, up to 20% of women who continue antidepressant use during pregnancy remain depressed,12 suggesting a lack of efficacy in some pregnant women. Currently, few studies have investigated the effects of antidepressant use during pregnancy on the neurodevelopment of children, including autism spectrum disorders (ASD). Given recent projections by the World Health Organization that depression will be the second leading cause of death by 2020,13 antidepressants are likely to remain widely used, including during pregnancy. Therefore, a better understanding of their long-term neurodevelopmental effects on children, when used during gestation, is a public health priority.

Autism Spectrum Disorders
Autism spectrum disorder (ASD) is defined as a neurodevelopmental disorder which is characterized by pervasive impairment of communication, language, and social interaction, and by repetitive/restricted and stereotyped patterns of behavior.14 According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), this complex disorder includes five subgroups: autistic disorder, Rett syndrome, childhood disintegrative disorder, pervasive developmental disorder—not otherwise specified (PDD–NOS), and Asperger syndrome.15 The diagnosis of ASD is made at 3 years of age on average. The estimated prevalence of ASD has increased over time from 0.04% in 1966 to approximately 1% today16,17 in the United States. This observed rise in the
prevalence of ASD can be partly attributed to extrinsic factors, including changes in the diagnostic criteria and their overlap with other diagnoses, better screening of the overall population (higher detection), and greater awareness of the general population. Nevertheless, both genetic and environmental factors could also be important in the increase in ASD prevalence over time. These factors may include de novo mutations, specific genes conferring susceptibility, advanced maternal age, maternal diseases such as diabetes and hypertension, and numerous other factors such as maternal age, race/ethnicity, education, birth year, sex, birth weight, infants born at KPNC facilities between 1995 and 1999 who had at least one International Classification of Diseases, 9th Revision (ICD-9) diagnosis of ASD between 1995 and 2002. Studies of the phenomenon of elevated platelet serotonin levels, termed hyperserotonemia, in rodents have shown an association between blood 5-HT levels and autistic-like behaviors. Furthermore, hyperserotonemia was observed in 30% of individuals with autism. Hence, dysfunction of the serotonin system during pregnancy following SSRI exposure could directly induce changes in fetal brain development.

Genetic Predispositions to Autism Spectrum Disorders

Accumulating evidence suggests that genetic factors contribute to the development of ASD. The genetic etiology of ASD was first reported in a twin study in 1977, and numerous twin studies have since been conducted. In particular, in Denmark, a study including 21 pairs of twins (11 monozygotic [MZ]; 10 dizygotic [DZ]) showed that 91% of MZ twins and 0% of DZ twins were concordant with regard to the presence of ASD. A British twin study suggested that 60% of MZ pairs were concordant for autism versus 0% for DZ pairs; in the same study, 92% of MZ pairs were concordant for a broader spectrum of related cognitive or social abnormalities versus 10% of DZ pairs. This later study also suggested that genetic susceptibility contributed strongly to autism and that multiple genes were involved. It remains, however, that the influence of genetic factors on the development of ASD is complex and the cause of ASD is unknown in the majority of cases.

On the other hand, family history studies have shown that the risk of ASD recurrence in another child was higher than the general population prevalence (1%), and ranged from 3 to 14%. A recent study indicated an even higher probability of ASD recurrence among siblings (18.7%; 95% confidence interval [CI]: 13.34–25.5%).

Gestational Use of Antidepressants, Especially SSRIs, and the Risk of ASD—Review of Published Studies

To date, seven published studies have explored the association between antidepressant use during pregnancy and the risk of ASD. The results of these studies are presented in Table 1 and are illustrated in Figs. 1 and 2.

Cren et al performed a population-based case–control study using data from the Kaiser Permanente Medical Care Program in Northern California (KPNC). Cases were defined as infants born at KPNC facilities between 1995 and 1999 who had at least one International Classification of Diseases, 9th Revision (ICD-9) diagnosis of ASD between 1995 and 2002. Children without ASD were randomly selected from the remaining cohort of live births and were matched to cases on sex, birth year, and hospital of birth (ratio of 5:1). Authors restricted the analysis to one child per mother. There were 298 cases of ASD, 20 (6.7%) of whom were exposed to an antidepressant, and 15 (5.0%) were exposed to SSRI only and 2 were exposed to SSRIs in combination with other antidepressants. After adjusting for maternal age, race/ethnicity, education, birth year, sex, hospital of birth, and birth weight, investigators found that antidepressant use during pregnancy was associated with an increased risk of ASD in the offspring (adjusted odds ratio [OR] = 2.0; 95% CI: 1.2–3.6). Authors also showed that cases of ASD were more than twice as likely to have been exposed to an SSRI in utero than the controls (adjusted OR = 2.1; 95% CI: 1.0–4.4), and the association for maternal history of mental disorders was made. The use of SSRIs during any trimester was also associated with an increased risk of ASD, but the association was only statistically significant during the first trimester (adjusted OR = 3.5; 95% CI: 1.5–7.9). In an analysis restricted to a subgroup of women with mental disorders in the United States, the association was not significant. Several biological mechanisms might underlie the association between prenatal selective serotonin reuptake inhibitor (SSRI) exposure and the occurrence of neurodevelopmental disorders, including ASD. Serotonin plays a critical role in the development of the brain. Studies have shown that serotonin modulates numerous pre- and postnatal processes, as well as developmental processes, including cell division, neuronal migration, cell differentiation, and synaptogenesis. Furthermore, some studies have suggested that serotonin acts as a morphogen during embryonic development, influencing the maturation of the brain. Experimental studies using rodent models have also indicated that transient inhibition of the serotonin transporter with fluoxetine hydrochloride, an SSRI, during brain development has consequences for behavior in later life, indicating a critical role for serotonin in the maturation of the brain systems.
### Table 1: Characteristics of the studies examining the association between antidepressant use during pregnancy and the risk of ASD

| Authors            | Source Population, country | Design                         | Exposure definition | Results (n, %) No. exposure cases/total no. of cases | Overall results OR/HR/RR 95%CI |
|--------------------|-----------------------------|--------------------------------|---------------------|-----------------------------------------------------|--------------------------------|
| Croen et al (2011) | N = 1,805                   | Population-based case–control study | SSRIs: 12 mo prior delivery | Any AD 20/298 (6.7%)                                | 12 mo before delivery SSRI OR: 2.1 (1.0–4.4) |
|                    | Kaiser Permanente Medical Care Program (KPNC) Northern California |                                | 1st trimester | SSRIs 15/298 (5.0)                                | First trimester SSRI OR: 3.5 (1.5–7.9) |
|                    |                             |                                | 2nd trimester | DAAs 2/298 (0.7)                                  | Second trimester SSRI OR: 1.5 (0.5–5.0) |
|                    |                             |                                | 3rd trimester SSRI | TCA 5/298 (1.7)                                    | Third trimester SSRI OR: 2.2 (0.7–6.9) |
| Sørensen et al (2013) | N = 668,468                 | Cohort study                    | During pregnancy | Any AD: 104/5,437 (1.9%)                           | Any AD during pregnancy HR: 1.2 (0.7–2.1) |
|                    | Danish Civil Registration System Denmark |                                | 1st trimester | Any SSRi: 91/5,437 (1.6%)                          | SSRI during pregnancy HR: 1.4 (0.8–2.4) |
|                    |                             |                                | 2nd trimester + 3rd trimester | Any SSRi: 91/5,437 (1.6%)                          | Sibling design: Any AD during pregnancy HR: 1.1 (0.5–2.3) SSRI during pregnancy HR: 0.9 (0.4–2.0) |
|                    |                             |                                |                      | SSRIs | Nonselective monoamine re-uptake inhibitors |
| Rai et al (2013)   | N = 54,472                  | Nested case–control study       | During pregnancy: Any AD | 21/1679 (1.25%)                                     | Any AD during pregnancy OR: 1.90 (1.15–3.14) |
|                    | Stockholm Youth cohort Sweden |                                | During pregnancy: SSRIs | Any AD during pregnancy OR: 1.65 (0.90–3.03) |
|                    |                             |                                |                      | Nonselective monoamine re-uptake inhibitors |
| Hviid et al (2013)  | N = 626,875                 | Cohort study                    | SSRI: during pregnancy | 122.6 per 100,000 person-year |

(Continued)
### Table 1 (Continued)

| Authors                  | Source Population, country                  | Design                      | Exposure definition          | Results (n, %) No. exposure cases/total no. of cases | Overall results OR/HR/RR 95%CI |
|--------------------------|---------------------------------------------|-----------------------------|------------------------------|-----------------------------------------------------|-------------------------------|
| Hviid et al (2013)        | Nationwide Medical Birth Registry Denmark   | SSRI: From 2 y before pregnancy through delivery | During pregnancy 52/3,892 (1.33%) | Rate ratio: 1.20 (0.90–1.61)                        |
|                          |                                             | SSRI: Only during pregnancy | From 2 y before pregnancy through delivery 29/3,892 (0.7%) | Rate ratio: 1.08 (0.74–1.58)                        |
|                          |                                             | SSRI: During 1st trimester  | Only during pregnancy 23/3,892 (0.6%) | Rate ratio: 1.40 (0.92–2.13)                        |
|                          |                                             |                             | During first trimester 40/3,892 (1.02%) | Rate ratio: 1.35 (0.97–1.87)                        |
| Harrington et al (2014)   | N = 966                                     | Population-based Case–control study | SSRI during pregnancy | Boys and girls 29/492 (5.9%) ASD vs. TD Boys and girls; OR: 1.55 (0.59–4.08) |
|                          | Genetics and the Environment (CHARGE) Study California | SSRI: 1st trimester | During pregnancy Boys only 25/421 (5.9%) ASD vs. TD Boys only; OR: 2.92 (1.07–7.93) Among maternal mental health subset: Boys and girls; OR: 1.86 (0.76–4.58) Boys only; OR: 3.17 (0.91–11.00) |
|                          |                                             | SSRI: 2nd trimester         |                             |                                                      |
|                          |                                             | SSRI: 3rd trimester         |                             |                                                      |
| Clements et al (2014)     | N = 5,399                                   | Case–control study          | During pregnancy            | During pregnancy: 2.9% During pregnancy OR: 1.10 (0.70–1.70) |
|                          | New England USA                             | AD: 1st trimester           | First trimester: 2.3%       | First trimester OR: 1.43 (0.85–2.38)                |
|                          |                                             | AD: 2nd trimester           | Second trimester: 2.0%      | Second trimester OR: 1.34 (0.77–2.27)               |
|                          |                                             | AD: 3rd trimester           | Third trimester: 1.8%       | Third trimester OR: 1.08 (0.61–1.88)                |
| Authors | Source Population, country | Design | Exposure definition | Results (n, %) | Overall results OR/HR/RR 95%CI |
|---------|---------------------------|--------|---------------------|----------------|--------------------------------|
| Boukhris et al (2014) | N = 145,456 Quebec Pregnancy Cohort | Cohort study | AD during 1st trimester | First trimester: 40/1,054 (3.80%) | Overall results HR: 1.87 (1.15–3.04) |
| | Quebec Pregnancy Cohort Quebec Canada | | AD during 2nd/3rd trimester: 31/1,054 (2.94%) | 2nd/3rd trimester: | HR: 1.87 (1.15–3.04) |
| | | | Any AD during 2nd/3rd trimesters | Stratification on family history of ASD | HR: 8.36 (0.31–221.71) |
| | | | SSRIs | With family history of ASD | HR: 1.87 (1.14–3.06) |
| | | | Without family history of ASD | HR: 1.87 (1.14–3.06) |
| | | | SNRIs | Any AD use during 2nd/3rd trimesters: | Stratification on maternal depression |
| | | | TCA | With maternal depression | HR: 1.75 (1.03–2.97) |
| | | | Others | Without maternal depression | HR: 1.36 (0.34–5.50) |

Abbreviations: AD, antidepressants; ASD, autism spectrum disorder; CI, confidence interval; DAA, dual-acting antidepressant; HR, hazard ratio; OR, odds ratio; RR, rate ratio; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TD, typical development.
the year before delivery, the risk of ASD was associated with any SSRI use during pregnancy (OR = 1.6; 95% CI: 0.6–4.0), but this association was not statistically significant. However, authors highlighted the possible misclassification of history of maternal mental disorders, which could have introduced bias in the stratified analyses. A second concern involved the small number of ASD-exposed cases in the second (n = 5) and third trimesters of pregnancy (n = 6), which limited statistical power for these analyses. Although they have used ICD9 codes for the identification of ASD, a subset of 50 children underwent clinical evaluation with the Autism Diagnostic Interview—Revised (ADI-R) and the Autism Diagnostic Observation Schedule—Generic (ADOS), and 94% (47/50) of them met the criteria for ASD. Although rates of ASD diagnoses have increased markedly over the past 20 years, analyses were adjusted for birth year.

In 2013, Rai et al\(^5\) (\(\text{- Table 1, - Figs. 1 and 2}\)) conducted a nested case–control study within the Stockholm Youth Cohort, including all young people (aged 0–17 years) registered between 2001 and 2007. Cases of ASD were defined using ICD-9 and ICD-10 codes, or DSM-IV criteria, and a multisource case ascertainment method, with registers covering all pathways of autism diagnosis and care within Stockholm County. Each case of ASD was matched to 10 controls without ASD on date of birth (month and year) and sex. Antidepressant use during pregnancy was reported by mothers at their first antenatal interview. A parental history of depression was obtained using the Stockholm County Adult Psychiatric Outpatient Register, which records the dates and diagnoses of individuals with visits to any outpatient psychiatric services in Stockholm County, and the Swedish National Patient Register, which contains the dates and discharge diagnoses of all inpatients and outpatients visits in Sweden. In this cohort, 1,679 cases of ASD were identified; 21 were exposed to antidepressants in utero. After adjustment for potential confounders, including any maternal psychiatric disorders, Rai et al\(^5\) reported a statistically significantly increased risk of ASD associated with antidepressant use during pregnancy (adjusted OR = 1.90; 95% CI: 1.15–3.14). They also found that the risk of ASD was 1.65 (95% CI: 0.90–3.03) and 2.69 (95% CI: 1.04–6.96) for the use of SSRIs and nonselective monoamine reuptake inhibitors during pregnancy, respectively. A history of depression and antidepressant use in pregnant mothers was strongly associated with ASD in their offspring (adjusted OR = 3.34; 95% CI: 1.50–7.47). In contrast, an association between antidepressant use during pregnancy and ASD was not seen among women reporting the use of these medications for reasons other than for depression. Again analyses were underpowered, and given that the prevalence of ASD has increased over time, detection bias could not be ruled out. However, authors attempted to control for this bias by matching cases and controls by date of birth.

Sørensen et al\(^5\) (\(\text{- Table 1, - Figs. 1 and 2}\)) conducted a cohort study of all children born in Denmark between 1996 and 2006, identified using the Danish Civil Registration System. Authors obtained information on maternal use of antidepressants during pregnancy from the Danish National Prescription Registry. Information on ASD diagnoses and parental psychiatric disorders were obtained from the Danish Psychiatric Central Register. Analyses were adjusted for parental age at conception, parental psychiatric history, gestational age at delivery, birth weight, sex of the newborn, and parity. Overall, 655,615 children were included in the cohort, 5,437 of who had a diagnosis of ASD; 8,833 (1.3%) were exposed to antidepressants in utero. When analyses were restricted to children of mothers with affective disorders, no statistically significant association was found between gestational use of antidepressants and the risk of ASD (adjusted hazard ratio [HR] = 1.2; 95% CI: 0.7–2.1). Similarly, no statistically significant association was found between SSRI

---

**Fig. 1** Risk of autism spectrum disorder associated with the use of any antidepressant during pregnancy. Note: no data were available on the risk of ASD associated with AD use during pregnancy in the studies by Harrington et al (2014)\(^5\) and Hviid et al (2013).\(^5\) "Odds ratio (OR); *hazards ratio (HR)/rate ratio (RR)."

**Fig. 2** Risk of autism spectrum disorder associated with the use of SSRI during pregnancy and the risk of ASD. Data were available for women aged 18–64 years at the first antenatal interview. A parental history of depression was obtained using the Stockholm County Adult Psychiatric Outpatient Register, which records the dates and diagnoses of individuals with visits to any outpatient psychiatric services in Stockholm County, and the Swedish National Patient Register, which contains the dates and discharge diagnoses of all inpatients and outpatients visits in Sweden. In this cohort, 1,679 cases of ASD were identified; 21 were exposed to antidepressants in utero. After adjustment for potential confounders, including any maternal psychiatric disorders, Rai et al\(^5\) reported a statistically significantly increased risk of ASD associated with antidepressant use during pregnancy (adjusted OR = 1.90; 95% CI: 1.15–3.14). They also found that the risk of ASD was 1.65 (95% CI: 0.90–3.03) and 2.69 (95% CI: 1.04–6.96) for the use of SSRIs and nonselective monoamine reuptake inhibitors during pregnancy, respectively. A history of depression and antidepressant use in pregnant mothers was strongly associated with ASD in their offspring (adjusted OR = 3.34; 95% CI: 1.50–7.47). In contrast, an association between antidepressant use during pregnancy and ASD was not seen among women reporting the use of these medications for reasons other than for depression. Again analyses were underpowered, and given that the prevalence of ASD has increased over time, detection bias could not be ruled out. However, authors attempted to control for this bias by matching cases and controls by date of birth.
exposure during pregnancy and the risk of ASD (adjusted HR = 1.4; 95% CI: 0.8–2.4). Findings did not vary by trimester of exposure. Using a sibling design, authors further restricted the cohort to include only families with at least two siblings and in which at least one had been diagnosed with ASD. In this analysis, no statistically significant association was found between prenatal exposure to any antidepressant (adjusted HR = 1.1; 95% CI: 0.5–2.3) or to SSRIs (adjusted HR = 0.9; 95% CI: 0.4–2.0) and ASD in children, suggesting that genetic predisposition is a stronger risk factor for ASD than gestational antidepressant use. However, sibling pairs with no ASD diagnosis were excluded from this analysis, resulting in partial adjustment for genetic predispositions. Indeed, exclusion of sibling pairs without ASD potentially led to overestimation of the association between family history of ASD and the risk of ASD in another child, and potentially underestimated the association between antidepressant use during pregnancy and ASD.

Hviid et al54 (►Table 1, ►Fig. 2) conducted a large population-based prospective cohort study in Denmark, using data from national registries (Medical Birth Registry, National Patient Register, National Prescription Registry, Danish Civil Registration System, and Danish Psychiatric Central Register) from 1996 to 2005, with follow-up through 2009. Only singleton births were included, and newborns with conditions associated with an increased risk of ASD, such as congenital rubella syndrome, were excluded. Only exposure to SSRI during pregnancy was considered. The authors took into account the effects of potential confounders, such as maternal age at pregnancy onset, smoking status during pregnancy, maternal psychiatric conditions, year of birth, use of medications other than SSRIs, and maternal level of education. Children were prospectively followed up from birth until January 1, 2010, or until the child’s 10th birthday. A total of 626,875 children were included, 6,068 (0.97%) of whom were exposed to SSRIs in utero. Exposure to SSRIs any time from 4 weeks before the beginning of pregnancy until delivery was associated with a 20% increased risk of ASD (adjusted rate ratio [RR] = 1.20; 95% CI: 0.90–1.61), but this estimate was not statistically significant. Results were similar when the analysis was restricted to SSRI use during pregnancy (adjusted RR = 1.40; 95% CI: 0.92–2.13). However, when SSRI exposure was limited to 6 to 24 months before pregnancy, the adjusted RR was 1.46 (95% CI: 1.17–1.81), suggesting that the observed association may be partly due to confounding by indication. To control for detection bias, Hviid et al54 adjusted for calendar year during which the follow-up assessment was made.

Harrington et al55 (►Table 1, ►Fig. 2) performed a population-based case–control study to investigate the association between prenatal SSRI exposure and the risk of ASD. The participants were families enrolled in the Childhood Autism Risks from Genetics and the Environment (CHARGE) study between April 2003 and August 2010. The population controls were identified using state birth files, and were matched to autism cases by age, sex, and regional center. ASD diagnoses were confirmed with ADI-R, and ADOS. The Vineland Adaptive Behavior Scales and the Mullen Scales of Early Learning were used to define developmental delay (DD). Maternal interviews were conducted to ascertain prenatal SSRI use, maternal mental health, and sociodemographic status. A total of 966 mother–child pairs were included: 492 with ASD, 154 with DD, and 320 with typical development; 48 (5%) mothers were prenatally exposed to SSRIs. After adjustment for potential confounders (regional center, child’s year of birth, and birthplace of mother), prenatal exposure to SSRIs was associated with a nonsignificant increased risk of ASD (adjusted OR = 1.55; 95% CI: 0.59–4.08); the association was, however, statistically significant among male children (adjusted OR = 2.92; 95% CI: 1.07–7.93). No significant associations were noted when restricting analyses to mothers with anxiety or mood disorder at any time before delivery. No adjustment was made for genetic predisposition to ASD; detection bias was taken into account by adjusting for the child’s year of birth.

Recently, Clements and colleagues (►Table 1, ►Fig. 1) published a case–control study on prenatal antidepressant exposure and the risk of ASD in a large health system database.56 Data on maternal health, ASD diagnosis, and antidepressant prescription were collected from electronic health records of a large health care system in Massachusetts, and were linked to birth records in the Massachusetts Registry of Vital Records and Statistics. Children with an ASD diagnosis were matched in a ratio of 1:3 with non-ASD children (controls) according to year of birth, delivery hospital, sex, insurance type, race/ethnicity, and prematurity status. Exposure to antidepressants was defined as (1) any time during pregnancy and (2) according to trimester of use. After adjustment for history of maternal depression, the risk of ASD associated with antidepressant exposure during pregnancy was elevated but not statistically significant (adjusted OR in first trimester = 1.43; 95% CI: 0.85–2.38; adjusted OR in second trimester = 1.34; 95% CI: 0.77–2.27). Considering the possibility of confounding by indication, the authors evaluated the association between the use of antidepressants before pregnancy (any time before the last menstrual period) and the risk of ASD. They reported that the use of antidepressants before pregnancy was significantly associated with ASD (adjusted OR = 1.62; 95% CI: 1.17–2.23) after adjustment for maternal history of depression. The authors stressed that a potential source of bias was the systematic misclassification of case and control status, which could have led to the nonsignificant estimates. Again, detection bias was adjusted for by taking into account year of birth.

Finally, Boukhris et al57 (►Table 1, ►Figs. 1 and 2) assessed the risk of ASD in children exposed to gestational antidepressants, taking into account potential confounding factors and any family history of ASD. A cohort study was conducted using data from the Quebec Pregnancy Cohort, and included data on all pregnancies and children in Quebec in 1998 to 2009. Only singleton births were considered in this study. Antidepressant use during pregnancy was defined as having at least one prescription filled during gestation, and according to the trimester of use; antidepressant classes were also studied (►Table 2). ASD outcomes were defined as infants with at least one diagnosis of ASD before December 31, 2009 (►Table 2). The cohort included 145,456 live-born children in 1998 to 2009; 1,054 (0.72%) children had a diagnosis of ASD.
The mean age of children at the end of follow-up was 6.24 years (standard deviation [SD] = 3.19). Adjusting for potential confounders, overall antidepressant use during the second or third trimester of pregnancy was statistically significantly associated with ASD (adjusted HR = 1.87; 95% CI: 1.15–3.04); SSRI use during the second or third trimester of pregnancy (adjusted HR = 2.17; 95% CI: 1.20–3.93) and the combined use of more than one antidepressant class during the same period (adjusted HR = 4.39; 95% CI: 1.44–13.32) was associated with the risk of ASD. To separate the effects of antidepressants from the underlying indication, a stratified analysis on maternal depression status was performed, resulting in a significantly increased risk of ASD associated with antidepressant use during the second or third trimester among children of depressed mothers (adjusted HR = 1.75; 95% CI: 1.03–2.97); no statistically significant association was found among nondepressed mothers (adjusted HR = 1.36; 95% CI: 0.34–5.50; 2 exposed cases). Genetic predispositions, defined as having a sibling with ASD, were further taken into account. In the subgroup of children with no genetic predisposition to ASD, second/third trimester use of antidepressants was increasing the risk of ASD (adjusted HR = 1.87; 95% CI: 1.14–3.06); having a child with ASD increased the risk of having another child with the disorder but nonstatistically significant (adjusted HR = 8.36; 95% CI: 0.31–221.71), which could be explained by the lack of power for analyses on this stratum. All analyses were adjusted for calendar year of birth to control for detection bias.

**Conclusion**

Taken together, studies are suggestive of an increased risk of ASD associated with antidepressant use during pregnancy. The hyperserotonemia in autistic patients provides a possible biological explanation for this association. Although, some findings are not statistically significant, this could partly be explained by lack of statistical power. Lack of statistical power should not be mistaken for lack of effect.

Presented studies used different approaches to control for the possible confounding effect of the indication (i.e., adjustment for maternal depression and other psychiatric disorders, sibling analysis, restricting the analysis to the children of mothers with affective disorders, and stratified analyses according to maternal depression status). Nevertheless, although confounding by indication was adjusted for in the majority of studies presented, we cannot completely rule out residual confounding by indication given the observational nature of the data. None of the seven studies controlled for the severity of maternal depression per se; however, Boukhris et al adjusted for proxies for severity, such as use of antidepressants before pregnancy, use of other antipsychotics, maternal diagnoses of other psychiatric disorders such as schizophrenia, and personality disorders. It remains that given the strength of the reported associations, serotonin inhibition during gestation seems to play an important role in the occurrence of ASD. Further research is needed to specifically assess the risk of ASD associated with antidepressant types and dosages during pregnancy. More research is also required to determine the most relevant temporal window of exposure during pregnancy.

**Acknowledgments**

Dr. Anick Bérard is a recipient of a career award from the Fonds de la Recherche en Santé du Québec (FRQ-S), and is on the endowment research Chair of the Famille Louis-Boivin for “Medications, Pregnancy and Lactation” at the

---

**Table 2** Characteristics of the study by Boukhris et al examining the association between antidepressant use during pregnancy and the risk of ASD

| Authors         | Definition of outcome | Years of Dx | Definition of exposure | Exposure period | Indication control |
|-----------------|-----------------------|-------------|------------------------|-----------------|-------------------|
| Boukhris et al (2014) | Children with ASD diagnosis between birth and the end of the study period (2009): Childhood autism (ICD-9 299.0 or ICD-10 F84.0) Atypical autism (ICD-9 299.0 or ICD-10 F84.1) Asperger syndrome (ICD-9 299.8 or ICD-10 F84.5) Other pervasive development disorders (ICD-9 299.8 or ICD-10 F84.8) Pervasive developmental disorder unspecified (ICD-9 299.9 or ICD-10 F84.9) | 1998–2009 | AD exposure was defined as having at least one prescription filled AD classes considered: SSRIs, SNRIs, TCAs, MAOIs, and others AD. A single class exposure was defined as the filling of prescriptions for only one AD classes. Combined classes of ADs were defined as the filling of a prescription for at least two or more different AD classes | 1. The year before the first day of gestation (1DG) defined as the first day of the last menstrual period 2. The 1st trimester of pregnancy defined as the time from the 1DG until the 14th completed week of gestation 3. The 2nd/3rd trimesters (between the 15th week until the end of pregnancy) | Maternal psychiatric disorders other than depression in the year prior (adjusted) Maternal depression/ anxiety/bipolar disorder (stratified) |

Abbreviations: AD, antidepressants; ASD, autism spectrum disorder; MAOI, monoamine oxidase inhibitor; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
Faculty of Pharmacy of the University of Montreal. This study was supported by the CIHR, “Quebec Training Network in Perinatal Research.”

References

1. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007;196(6):544.e1–544.e5
2. Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001–2006). Clin Ther 2012;34(1):239–249.e2
3. Kjaersgaard MI, Parner ET, Vestergaard M, et al. Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study. PLoS ONE 2013;8(8):e72095
4. Gentile S. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand 2011;123(4):266–275
5. Moors KE, Poole C, Ephross SA, Olsan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88(3):159–170
6. Ross LE, Grigoriadis S, Mamasashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013;70(4):436–443
7. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158(4):312–316
8. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90(3):288–291
9. De Vera MA, Bérard A. Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension. Br J Clin Pharmacol 2012;74(2):362–369
10. Yonkers KA, Gotman N, Smith MV, et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 2011;22(6):848–854
11. Cohen LS, Nonacs RM, Bailey JW, et al. Relapse of depression during pregnancy following antidepressant discontinuation: a preliminary prospective study. Arch Women Ment Health 2004;7(4):217–221
12. Berard A, Karam F, Sheehy O, et al. Antidepressant use during pregnancy and the risk of delay in overall cognitive development at one year old: results from the OTIS Antidepressants Study. Birth Defects Res A Clin Mol Teratol 2012;94:253–269
13. Christopher M, Alan L, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Geneva: Harvard School of Public Health; 1996
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.4th ed. Washington, DC: American Psychiatric Association; 2000
15. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics 2004;113(5):e472–e486
16. Kogan MD, Blumberg SJ, Schieve LA, et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009;124(5):1395–1403
17. Centers for disease Control and Prevention (CDC) MMWR Surveill Summ. Prevalence of Autism Spectrum Disorders—Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008. 2012;61(3):2–18. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6103a1.htm. Accessed March 30, 2012
18. Hertz-Picciotto I, Delwiche L. The rise in autism and the role of age at diagnosis. Pediatrics 2009;20(1):84–90
19. Hertz-Picciotto I. Commentary: Diagnostic change and the increased prevalence of autism. Int J Epidemiol 2009;38(5):1239–1241, author reply 1243–1244
20. Hertz-Picciotto I, Croen LA, Hansen R, Jones CR, van de Water J, Pessah IN. The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. Environ Health Perspect 2006;114(7):1119–1125
21. Ronen M, Lisoissof I, Levy D, Wigler M. The role of de novo mutations in the genetics of autism spectrum disorders. Nat Rev Genet 2014;15(2):133–141
22. Sandin S, Hultman CM, Kolevzon A, Gross R, MacCabe JH, Reichenberg A. Advancing maternal age is associated with increasing risk for autism: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2012;51(5):477–486
23. Lyall K, Pauls DL, Spiegelman D, Ascherio A, Santangelo SL. Pregnancy complications and obstetric suboptimality in association with autism spectrum disorders in children of the Nurses’ Health Study II. Autism Res 2012;5(1):21–30
24. Moore GS, Kneitel AW, Walker CK, Gilbert WM, Xing G. Autism risk in small- and large-for-gestational-age infants. Am J Obstet Gynecol 2012;206(4):314.e1–314.e9
25. Daniels JL, Forssen U, Hultman CM, et al. Parental psychiatric disorders associated with autism spectrum disorders in the offspring. Pediatrics 2008;121(5):e1357–e1362
26. Jokiranta E, Brown AS, Heinimaa M, Cheshlack-Postava K, Suominen A, Sourander A. Parental psychiatric disorders and autism spectrum disorders. Psychiatry Res 2013;207(3):203–211
27. Folstein S, Rutter M. Infantile autism: a genetic study of 21 twin pairs. J Child Psychol Psychiatry 1977;18(4):297–321
28. Steffenburg S, Gillberg C, Hellgren L, et al. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psychiatry 1989;30(3):405–416
29. Bailey A, Le Couteur A, Gottesman I, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995;25(1):63–72
30. Piven J, Vieland VJ, Parlier M, et al. A molecular genetic study of autism and related phenotypes in extended pedigrees. J Neurodev Disord 2013;5(1):30
31. Sumi S, Taniai H, Miyachi T, Tanemura M. Sibling risk of pervasive developmental disorders associated with autism spectrum disorders. JAMA 2013;310(10):1059–1067
32. Ritvo ER, Jorde LB, Mason-Brothers A, et al. The UCLA-University of Utah epidemiologic survey of autism: recurrence risk estimates and genetic counseling. Am J Psychiatry 1989;146(8):1032–1036
33. Ozonoff S, Young GS, Carter A, et al. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics 2011;128(3):e489–e495
34. Whitaker-Azmitia PM. Serotonin and brain development: role in human developmental diseases. Brain Res Bull 2004;61(6):518–522
35. Lillova G, Rehák P, Veselá J, et al. Serotonin localization and its functional significance during mouse preimplantation embryo development. Zygote 2004;12(3):205–213
36. Angrisani MD, Zhou M, Lira A, Hen R, Gingrich JA. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004;306(5697):879–881
37. Oberlander TF, Gingrich JA. Angrisani MS. Sustained neurobehavioral effects of exposure to SSRIs antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 2009;86(6):672–677
38. Chugani DC, Muzik O, Behen M, et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999;45(3):287–295
Chandana SR, Behen ME, Juhász C, et al. Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism. Int J Dev Neurosci 2005;23(2-3):171–182

Murphy DG, Daly E, Schmitz N, et al. Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger’s syndrome: an in vivo SPECT study. Am J Psychiatry 2006;163(5):934–936

Hanley HG, Stahl SM, Freedman DX. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry 1977;34(5):521–531

Tordjman S, Anderson GM, Cohen D, et al. Presence of autism, hyperserotonemia, and severe expressive language impairment in Williams-Beuren syndrome. Mol Autism 2013;4(1):29

Kahne D, Tudorica A, Borella A, et al. Behavioral and magnetic resonance spectroscopic studies in the rat hyperserotonemic model of autism. Physiol Behav 2002;75(3):403–410

Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 1961;58:315–320

Marazziti D, Muratori F, Cesari A, et al. Increased density of the platelet serotonin transporter in autism. Pharmacopsychiatry 2000;33(5):165–168

Cook EH, Leventhal BL. The serotonin system in autism. Curr Opin Pediatr 1996;8(4):348–354

Anderson GM. Monoamines in autism: an update of neurochemical research on a pervasive developmental disorder. Med Biol 1987;65(2-3):67–74

Ansoe MS, Hen R, Gingrich JA. Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol 2007;7(1):8–17

Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011;68(11):1104–1112

Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 2013;346:f2059

Sørensen MJ, Grønborg TK, Christensen J, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol 2013;5:449–459

Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med 2013;369(25):2406–2415

Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics 2014;133(5):e1241–e1248

Clements CC, Castro VM, Blumenthal SR, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry 2014

Boukhris T, Sheehy O, Bérard A. Antidepressant use during pregnancy is increasing the risk of autism spectrum disorder even after taking genetic predisposition into account. J Popul Ther Clin Pharmacol 2014;21(2):e308–e337